info@seagull-health.com
SeagullHealth
语言:
search
new
How to use Duvyzat
501
Article source: Seagull Pharmacy
Jul 16, 2025

Duvyzat (Givinostat) is a drug used to treat Duchenne muscular dystrophy (DMD) for patients 6 years and older. The drug is a histone deacetylase (HDAC) inhibitor that slows disease progression by regulating gene expression.

How to use Duvyzat

Correct use of Duvyzat is the key to clarifying the therapeutic effect. The following content will detail its usage and dosage, adverse reaction management, and precautions to help patients use the drug safely.

Usage and Dosage

The recommended dose of Duvyzat is based on the patient's weight and should be taken twice a day with food. The specific dose is as follows: 22.2 mg (about 2.5 ml) per dose for patients weighing 10-20 kg; 31 mg (about 3.5 ml) per dose for patients weighing 20-40 kg; 44.3 mg (about 5 ml) per dose for patients weighing 40-60 kg; 53.2 mg (about 6 ml) per dose for patients weighing 60 kg and above. Shake the bottle thoroughly before administration and use a graduated oral syringe to accurately measure the dose.

Adverse reaction management

Duvyzat may cause adverse reactions such as thrombocytopenia, diarrhea or elevated triglycerides. If these occur, the dose needs to be adjusted according to body weight. For example, the first dose of patients weighing 10-20 kg can be reduced to 17.7 mg, and if symptoms persist, it can be further reduced to 13.3 mg. If the adjustment still fails to relieve symptoms, it is recommended to stop the drug and seek medical attention.

Rational use of Duvyzat requires strict adherence to dosage instructions and timely treatment of adverse reactions. Patients should monitor relevant indicators regularly to ensure drug safety.

How to buy Duvyzat

Duvyzat is not currently available in China, and patients need to purchase it through specific channels. The following content will introduce its manufacturer, price and purchase precautions.

Manufacturer and price

Duvyzat is produced by Italfarmaco S.p.A. in Spain, with a specification of 140ml/box. This drug is an original drug, its price is relatively high, and there are currently no generic drugs on the market.

Purchase precautions

Since Duvyzat is not included in China's medical insurance, patients need to purchase it through overseas channels. When purchasing, you need to pay attention to the authenticity and storage conditions of the drug, and make sure that the drug meets the requirements during transportation. After opening the bottle, it must be used within 60 days, and the unused part should be discarded.

When purchasing Duvyzat, you need to carefully choose the channel and pay attention to the storage and expiration date of the drug. Patients can consult professional medical institutions or pharmacies for more purchase guidance.

Pharmacokinetics of Duvyzat

Understanding the pharmacokinetics of Duvyzat helps optimize the medication regimen. The following content will introduce its absorption characteristics, food effects, and interactions with other drugs.

Absorption and food effects

Duvyzat reaches peak blood concentration about 2-3 hours after oral administration. When taken with a high-fat meal, the drug exposure (AUC) increases by about 40%, the peak concentration (Cmax) increases by 23%, and the peak time is delayed. Therefore, it is recommended to take it with food to enhance the efficacy.

Drug interactions

Duvyzat may interact with other drugs. It is a weak intestinal CYP3A4 inhibitor, which may affect the blood concentration of CYP3A4 sensitive substrates. In addition, it should be avoided to use it with drugs that prolong the QT interval to avoid increasing the risk of arrhythmias.

Understanding the pharmacokinetic characteristics of Duvyzat can help patients better plan medication time and diet, while avoiding potential drug interactions.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Duvyzat(Givinostat)
Duvyzat(Givinostat)
Male patients aged 6 years and older with genetically confirmed DMD.
WeChat Scan
Free Inquiry
Recommended Articles
Duvyzat's role and efficacy
Duvyzat (givinostat) is an innovative drug for the treatment of Duchenne muscular dystrophy (DMD). It regulates gene expression by inhibiting histone deacetylase (HDAC) and delays disease progression....
Duvyzat givinostat side effects
Duvyzat (Givinostat) is a histone deacetylase inhibitor for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and above. Some side effects may occur during the use of Duvyzat...
Instructions for Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy
Duvyzat (givinostat) is the first non-steroidal drug approved by the US FDA for all genetic variant types of Duchenne muscular dystrophy (DMD). The drug slows disease progression by targeting the acti...
Indications of Duvyzat
Duvyzat (givinostat) is an innovative drug for the treatment of Duchenne muscular dystrophy (DMD) for patients aged 6 years and above. It works by inhibiting histone deacetylase (HDAC), becoming the f...
Duvyzat's role
Duvyzat (givinostat) is a novel histone deacetylase (HDAC) inhibitor, mainly used to treat Duchenne muscular dystrophy (DMD). It is suitable for patients aged 6 years and above, regardless of their ge...
Instructions for NEXVIAZYME
NEXVIAZYME (alglucosidase α) is a drug for the treatment of Pompe disease. Its detailed Chinese instructions, purchase channels and precautions are important for patients. This article aims to provide...
NEXVIAZYME instructions, medical insurance, price, efficacy, side effects
NEXVIAZYME is a drug for the treatment of Pompe disease. Its instructions, medical insurance status, price, efficacy and side effects are important for patients. This article aims to provide patients ...
How to buy NEXVIAZYME
NEXVIAZYME was developed by the French Sanofi Group and is a treatment for Pompe disease. It has been successfully launched and has accumulated rich clinical experience, bringing new hope for tre...
Related Articles
Duvyzat's role
Duvyzat (givinostat) is a novel histone deacetylase (HDAC) inhibitor, mainly used to treat Duchenne muscular dystrophy (DMD). It is suitable for patients aged 6 years and above, regardless of their ge...
How to use Duvyzat
Duvyzat (Givinostat) is a drug used to treat Duchenne muscular dystrophy (DMD) for patients 6 years and older. The drug is a histone deacetylase (HDAC) inhibitor that slows disease progression by regu...
Duvyzat's role and efficacy
Duvyzat (givinostat) is an innovative drug for the treatment of Duchenne muscular dystrophy (DMD). It regulates gene expression by inhibiting histone deacetylase (HDAC) and delays disease progression....
Duvyzat givinostat side effects
Duvyzat (Givinostat) is a histone deacetylase inhibitor for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and above. Some side effects may occur during the use of Duvyzat...
Instructions for Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy
Duvyzat (givinostat) is the first non-steroidal drug approved by the US FDA for all genetic variant types of Duchenne muscular dystrophy (DMD). The drug slows disease progression by targeting the acti...
Indications of Duvyzat
Duvyzat (givinostat) is an innovative drug for the treatment of Duchenne muscular dystrophy (DMD) for patients aged 6 years and above. It works by inhibiting histone deacetylase (HDAC), becoming the f...
How to buy Duvyzat
Duvyzat (Givinostat) is a new drug for the treatment of Duchenne muscular dystrophy (DMD). Its unique non-steroidal properties and effectiveness for all genetic variant DMD patients make it the focus ...
How much is a box of Duvyzat?
Duvyzat (Givinostat) is an innovative drug used to treat Duchenne muscular dystrophy (DMD). It is important for patients and their families to understand its price, treatment effects, and dietary prec...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved